 Home > Active Ingredient News > Drugs Articles > The U.S. FDA grants Zebutinib accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma

The U.S. FDA grants Zebutinib accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma

 Last Update: 2021-10-01
 Source: Internet
 Author: User

Tags

full time near

1 4 all thread

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 15th, BeiGene announced that the U.
S.
Food and Drug Administration (FDA) has granted accelerated approval to Baiyueze® (Zebutinib) for the treatment of relapsed or refractory patients who have received at least one anti-CD20 treatment Adult patients with sexual (R/R) marginal zone lymphoma (MZL)
.

This accelerated approval is based on overall response rate (ORR) results
.

The subsequent full approval of this indication will depend on whether the confirmatory test can further confirm the patient's clinical benefit

The FDA approval is based on the effectiveness of two single-arm clinical trials.
The primary endpoints of these two trials are ORR evaluated by the Independent Review Committee (IRC) based on the 2014 Lugano classification criteria
.

A multicenter, pivotal Phase 2 MAGNOLIA clinical trial (NCT03846427) evaluated the efficacy of Baiyueze® in R/R MZL patients who have received at least 1 line of anti-CD20 therapy
.

A total of 66 patients were enrolled in the study, 26 of which were extranodal subtypes, 26 were lymph node subtypes, 12 were splenic subtypes, and 4 were unknown subtypes

Another global Phase 1/2 study BGB-3111-AU-003 (NCT02343120) evaluated 20 patients with MZL, including 9 extranodal subtypes, 5 lymph node subtypes, and 6 splenic subtypes
.

Based on the evaluation of CT scan, the ORR obtained by Baiyueze® was 80% (95% CI: 56.

The most common (≥30%) adverse reactions of Baiyueze®, including abnormal detection data in 847 patients, are neutropenia, upper respiratory tract infection, thrombocytopenia, bleeding, lymphopenia, Skin rash and musculoskeletal pain
.

The recommended dosage of Baiyueze® is 160mg twice a day or 320mg once a day, either on an empty stomach or after meals
.

The dosage can be adjusted according to the adverse reaction.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$49-62/KG FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.